Clinical trials: Transformed Migraine
Chronic Migraine
Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine
A prospective, single arm, open-label, multicenter trial to assess the efficacy and safety of the Nerivio device in chronic migraine patients.
- Trial name
- NCT04194008
- Testing
- Nerivio
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- Theranica
Chronic Migraine
Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache
The purpose of this study is to study MIGRA-ZEN RELIEF PLUS, an all-natural herbal dietary supplement product, with respect to alleviating and/or stopping migraine headache pain compared to a placebo when used prophylactically.
- Trial name
- RZN (NCT01135784)
- Testing
- MIGRA-ZEN RELIEF PLUS
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- RZN Nutraceuticals, Inc.
Migraine, Chronic Migraine
Pilot Study for a Machine Learning Test for Migraine
This study is a single center, random participant selection, data analyst is blinded to patient identifiers, controlled clinical trial.
- Conditions
- Migraine, Chronic Migraine, Tension-Type Headache
- Trial name
- MLTM (NCT05517200)
- Testing
- Machine Learning Test for Migraine
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Headache Sciences Incorporated
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
- Trial name
- NCT01662492
- Testing
- Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2
- Where
- 22 sites in United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Chronic Migraine
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck.
- Trial name
- MINT-C (NCT07018713)
- Testing
- Xeomin
- Where
- 111 sites in United States, Austria and 11 more
- Volunteers
- 808 people
- Sponsor
- Merz Therapeutics GmbH
Migraine Disorders, Headache
Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat Chronic Migraine in clinical practice.
- Trial name
- NCT01976611
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 402 people
- Sponsor
- Allergan
Migraine
A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches
The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo for the prevention of headaches in patients with chronic migraine.
- Trial name
- NCT00210912
- Testing
- topiramate
- Volunteers
- 328 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Migraine
Post-marketing Clinical Follow-up for Long-term Use of Intranasal Kinetic Oscillation in Subjects With Chronic Migraine
An non controlled, long term, multi center investigation
- Trial name
- NCT05843721
- Testing
- KOS (Intranasal kinetic oscillation stimulation)
- Where
- 12 sites in Germany, Israel and 2 more
- Volunteers
- 98 people
- Sponsor
- Chordate Medical
Migraine
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
- Trial name
- NCT04825678
- Testing
- Erenumab
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Amgen
Chronic Migraine
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
- Trial name
- REGAIN (NCT02614261)
- Testing
- Galcanezumab
- Where
- 117 sites in United States, Argentina and 11 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
It will provide a first evaluation of efficacy, safety and tolerability of BGG492 in patients with non-chronic migraine having more than 3 and less than 12 migraine attacks per 4 weeks.
- Trial name
- NCT01617941
- Testing
- BGG492
- Sponsor
- Novartis Pharmaceuticals
Chronic Migraine
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
Migraine imposes a substantial burden on patients in terms of diminished daily functioning, quality of life, and financial loss.
- Trial name
- Tx360 (NCT01709708)
- Testing
- Marcaine, Saline
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tian Medical Inc.
Chronic Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age.
- Trial name
- REBUILD-2 (NCT04616326)
- Testing
- Galcanezumab
- Where
- 88 sites in United States, Denmark and 9 more
- Volunteers
- 312 people
- Sponsor
- Eli Lilly and Company
Episodic Migraine, Chronic Migraine
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
- Trial name
- NCT04686136
- Testing
- Atogepant 60 mg
- Where
- 116 sites in United States, Canada and 12 more
- Volunteers
- 596 people
- Sponsor
- AbbVie
Chronic Migraine Headache
Clinical Exploration of NEUROMARK System in Participants With Chronic Migraine
Clinical exploration of NEUROMARK System in Participants with Chronic Migraine
- Trial name
- NCT06862674
- Testing
- NEUROMARK System
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Neurent Medical